BIL	Quotation Reference	Description	Advertisement Date	Closing Date (Not Later Than 2.00PM)	Quotation Fee	Requesting Department	Focal Person
		1. CHLOROCRESOL BP -	PR depth of the control of the contr				
A de principal de la companya de la		QUANTITY: 35 x 250G					
		2. PROPYLENE GLYCOL –					I FAINW MÁ DI YANI
A COLOR OF THE COL		QUANTITY: 111 x 2.5 LITRE					LENNY MARLIANI BINTI HAJI RAMLI PHARMACIST,
10	DRPS/QTN/160/2022	3. SULPHUR SUBLIME POWDER BP	16/11/2022	03/12/2022	\$5,00	JABATAN PERKHIDMATAN FARMASI	DRUG TEL: 2393298 EXT. 228
		QUANTITY: 15 × 500G		College of popularity and a constraint of the college of the colle		The state of the s	
		PLACE OF SUBMISSION: QUOTATION BOX (GROUND FLOOR) MINISTRY OF HEALTH COMMONWEALTH DRIVE BANDAR SERI BEGAWAN, BB 3910 NEGARA BRUNEI DARUSSALAM					

QTN REF: DRPS/QTN/ 160 /2022

#### SUPPLY AND DELIVERY OF MEDICINES FOR THE DEPARTMENT OF PHARMACEUTICAL SERVICES.

NO	DESCRIPTION OF ITEM	QUANTITY	BRAND	MANUFACTURER AND ORIGIN	UNIT PRICE	TOTAL PRICE
1.	Chlorocresol BP	35 x 250g				New Area (Miller) and Art (Miller) and Miller (Miller) and Miller (Miller) are all thick and the condition are
2.	Propylene glycol	11 x 2.5Litre				
3.	Sulphur Sublime powder BP	15 x 500g				
		Avoising the second sec				

## **DELIVERY PERIOD:**

First order 2 months, subsequent order ex-stock

# **DELAY AND LIQUIDATED DAMAGES:**

If the Supplier fails or is unable to deliver the Goods or any parts thereof on the Delivery Date within the time specified, the Government shall be entitled, without prejudice to claim from the Supplier by way of liquidated damages for each day of such delay, a sum of equal to one percent (1%) of the price of the Goods as stated in the relevant Purchase Order in respect of the delayed delivery, provided that the total liquidated damages shall not exceed the Purchase Order Price.

## PRICE VALIDITY:

The quotation shall remain valid for 6 MONTHS from the final date for the submission of the quotation, during which no supplier may withdraw his/her quotation. Where the price validity differs from that required by the Government i.e. 6 months, the LONGER VALIDITY PERIOD will be taken as the final validity period.

QTN REF: DRPS/QTN/ 160 /2022

# SUPPLY AND DELIVERY OF MEDICINES FOR THE DEPARTMENT OF PHARMACEUTICAL SERVICES

a.	Tenderer must be registered with the Ministry of Health	Acknowledgement:	Company's Official Stamp
<b>b</b> .	Please fill in the QUOTATION FORM completely including the USER REQUIREMENT FORM (if available). Submission of incomplete form may cause DISQUALIFICATION OF QUOTATION	I hereby certify the above quote to be correct.  Signature:	
÷.	Each tenderer is allowed to quote ONE BRAND WITH ONE PRICE ONLY for each item. Submission of more than one brand and price will cause DISQUALIFICATION OF QUOTATION	Name:	
d.	Delivery Period:  FIRST ORDER 2 MONTHS, SUBSEQUENT ORDER EX- STOCK	Designation:	
e.	Please do not use TIPPEX for amendment	Date:	

	The Pharmacist Drug Procurement.	Date:		
	3 <sup>rd</sup> Floor, Pharmacy Administration Department of Pharmaceutical Services Ministry of Health	Your Ref	;	
	MISSION OF SAMPLES & RELEVANT PRODUC QUOTATION REF: DRPS/QTN/ 160 / 2022	T DOCUMENTS e.	g : COA	
quot	mple submission & documents to be sent t ation advertisement along with a copy of this f use attention to the Pharmacist).		rement <u>before</u>	e closing
	e original copy of this form is to be submitted quotation advertisement.	I to the Drug Proc	urement befor	e closing
<del></del>				
The a	above quotation refers.			
We a	above quotation refers. tre pleased to inform you that the samples we hav Quality Control Section as on the closing date, an	e submitted and No e indicated as follov	t submitted to t	he
We a	re pleased to inform you that the samples we hav	e submitted and No e indicated as follow Sample Submitted Indicate √	t submitted to t vs:- Sample NOT submitted Indicate X	Not offered
We a	tre pleased to inform you that the samples we have Quality Control Section as on the closing date, an	Sample Submitted	Sample NOT submitted	Not offered
We a Drug	tre pleased to inform you that the samples we have Quality Control Section as on the closing date, and items	Sample Submitted	Sample NOT submitted	

Please submit the Form to the Drug Procurement the latest ONE WEEK after closing of Quotation Advertisement.

Please stamp the Form with your company chop.

Position: Company: QTN REF: DRPS/QTN/160/2022

Requirements	Enter Response Here
Presentation  Vendor is to submit:  vii. Details of the pack size and packaging offered.  viii. Clear colour-printed photo images of the product offered with supplier's / tenderer's official stamp.  Photo images must show label details of the primary and secondary packaging including name / brand of	
item, strength and form / preparation, from all sides/angles.  ix. High resolution photo images of the following  • For tablets / capsules:  • Appearance of individual tablets / capsules;  • If the item is in strip pack, the back and front of the strip  • For Injections:  • Appearance of individual vial / ampoule / syringe	
Shelf life  Minimum of 24 months on receipt unless the item has short expiry (e.g. vaccines) or agreed to be accepted by MoH prior to bringing in the stock. Please indicate the product shelf-life.	
Vendor is required to submit sample in untampered original pack including package insert, which must be enclosed during the packaging process at manufacturer level at the point of submission. (For Controlled drugs and Psychotropic drugs see 'Presentation')	

Certificate of Analysis  A copy of the product's Certificate of Analysis (CoA) is to be submitted. A copy of the product's Certificate of Analysis is required to accompany each consignment supplied. The CoA should match the product sample submitted.  Storage condition  The storage labelling should be in accordance with ASEAN stability guideline and should be based on the stability evaluation of the drug product.  Specific temperature for storage condition should be indicated. Terms such as "ambient conditions", "room temperature" or "does not require any special storage condition" will not be considered unless stability studies are provided.  New Product  Where the product offered has never been supplied to the Ministry of Health, Brunei, detailed information (to be provided in electronic copy on CD-ROM) on the product is to be submitted. The information required include, but not limited to, the following:  (i) Bioequivalence studies (Generic products) and / or Clinical studies  (ii) Source for raw material / Active pharmaceutical ingredient  (iv) Source Scertificate of Analysis for finished products  Sales record to local and overseas customers presented as the quantities sold to each country per year  (v) A copy of the Summary of Product Characteristics/Package Insert  (v) Declaration of source of animal origin and alcohol content (if any).  (vii) Good Manufacturing Practice (GMP) certificate  (viii) Batch release certificate or certificate of origin (for blood products)  (v) Certificate of suitability, where applicable	Requirements	Enter Response Here
be submitted. A copy of the product's Certificate of Analysis is required to accompany each consignment supplied. The CoA should match the product sample submitted.  Storage condition  The storage labelling should be in accordance with ASEAN stability guideline and should be based on the stability evaluation of the drug product.  Specific temperature for storage condition should be indicated. Terms such as "ambient conditions", "room temperature" or "does not require any special storage condition" will not be considered unless stability studies are provided.  New Product  Where the product offered has never been supplied to the Ministry of Health, Brunei, detailed information (to be provided in electronic copy on CD-ROM) on the product is to be submitted. The information required include, but not limited to, the following:  (i) Bioequivalence studies (Generic products) and / or Clinical studies  (ii) Source for raw material / Active pharmaceutical ingredient  (iv) Source & Certificate of Analysis for finished products (iv) Sales record to local and overseas customers presented as the quantities sold to each country per year  (v) A copy of the Summary of Product Characteristics/Package Insert  (vi) Declaration of source of animal origin and alcohol content (if any).  (vii) Good Manufacturing Practice (GMP) certificate  (viii) Batch release certificate or certificate of origin (for blood products)	Certificate of Analysis	
stability guideline and should be in accordance with ASEAN stability guideline and should be based on the stability evaluation of the drug product.  Specific temperature for storage condition should be indicated. Terms such as "ambient conditions", "room temperature" or "does not require any special storage condition" will not be considered unless stability studies are provided.  New Product  Where the product offered has never been supplied to the Ministry of Health, Brunei, detailed information (to be provided in electronic copy on CD-ROM) on the product is to be submitted. The information required include, but not limited to, the following:  (i) Bioequivalence studies (Generic products) and / or Clinical studies (ii) Sability studies (iii) Source for raw material / Active pharmaceutical ingredient (iv) Source & Certificate of Analysis for finished products (iv) Sales record to local and overseas customers presented as the quantities sold to each country per year (v) A copy of the Summary of Product Characteristics/Package Insert (vi) Declaration of source of animal origin and alcohol content (if any). (vii) Good Manufacturing Practice (GMP) certificate (viii) Batch release certificate or certificate of origin (for blood products) (ix) Certificate of suitability, where applicable	be submitted. A copy of the product's Certificate of Analysis is required to accompany each consignment supplied. The CoA should match the product sample	
stability guideline and should be based on the stability evaluation of the drug product.  Specific temperature for storage condition should be indicated. Terms such as "ambient conditions", "room temperature" or "does not require any special storage condition" will not be considered unless stability studies are provided.  New Product  Where the product offered has never been supplied to the Ministry of Health, Brunei, detailed information (to be provided in electronic copy on CD-ROM) on the product is to be submitted. The information required include, but not limited to, the following:  (i) Bioequivalence studies (Generic products) and / or Clinical studies  (ii) Stability studies  (iii) Source for raw material / Active pharmaceutical ingredient  (iv) Source & Certificate of Analysis for finished products  (iv) Sales record to local and overseas customers presented as the quantities sold to each country per year  (v) A copy of the Summary of Product Characteristics/Package Insert  (vi) Declaration of source of animal origin and alcohol content (if any).  (vii) Good Manufacturing Practice (GMP) certificate  (viii) Batch release certificate or certificate of origin (for blood products)  (ix) Certificate of suitability, where applicable	Storage condition	
indicated. Terms such as "ambient conditions", "room temperature" or "does not require any special storage condition" will not be considered unless stability studies are provided.  New Product  Where the product offered has never been supplied to the Ministry of Health, Brunei, detailed information (to be provided in electronic copy on CD-ROM) on the product is to be submitted. The information required include, but not limited to, the following:  (i) Bioequivalence studies (Generic products) and / or Clinical studies (ii) Stability studies (iii) Source for raw material / Active pharmaceutical ingredient (iv) Source & Certificate of Analysis for finished products (iv) Sales record to local and overseas customers presented as the quantities sold to each country per year (v) A copy of the Summary of Product Characteristics/Package Insert (vi) Declaration of source of animal origin and alcohol content (if any). (vii) Good Manufacturing Practice (GMP) certificate (viii) Batch release certificate or certificate of origin (for blood products) (ix) Certificate of suitability, where applicable	stability guideline and should be based on the stability	
Where the product offered has never been supplied to the Ministry of Health, Brunei, detailed information (to be provided in electronic copy on CD-ROM) on the product is to be submitted. The information required include, but not limited to, the following:  (i) Bioequivalence studies (Generic products) and / or Clinical studies (ii) Stability studies (iii) Source for raw material / Active pharmaceutical ingredient (iv) Source & Certificate of Analysis for finished products (iv) Sales record to local and overseas customers presented as the quantities sold to each country per year (v) A copy of the Summary of Product Characteristics/Package Insert (vi) Declaration of source of animal origin and alcohol content (if any). (vii) Good Manufacturing Practice (GMP) certificate (viiii) Batch release certificate or certificate of origin (for blood products) (ix) Certificate of suitability, where applicable	indicated Terms such as "ambient conditions", "room temperature" or "does not require any special storage condition" will not be considered unless stability studies are	
Ministry of Health, Brunei, detailed information (to be provided in electronic copy on CD-ROM) on the product is to be submitted. The information required include, but not limited to, the following:  (i) Bioequivalence studies (Generic products) and / or Clinical studies (ii) Stability studies (iii) Source for raw material / Active pharmaceutical ingredient (iv) Source & Certificate of Analysis for finished products (iv) Sales record to local and overseas customers presented as the quantities sold to each country per year  (v) A copy of the Summary of Product Characteristics/Package Insert (vi) Declaration of source of animal origin and alcohol content (if any).  (vii) Good Manufacturing Practice (GMP) certificate (viii) Batch release certificate or certificate of origin (for blood products) (ix) Certificate of suitability, where applicable	New Product	
Clinical studies  (ii) Stability studies  (iii) Source for raw material / Active pharmaceutical ingredient  (iv) Source & Certificate of Analysis for finished products  (iv) Sales record to local and overseas customers presented as the quantities sold to each country per year  (v) A copy of the Summary of Product Characteristics/Package Insert  (vi) Declaration of source of animal origin and alcohol content (if any).  (vii) Good Manufacturing Practice (GMP) certificate  (viii) Batch release certificate or certificate of origin (for blood products)  (ix) Certificate of suitability, where applicable	Ministry of Health, Brunei, detailed information (to be provided in electronic copy on CD-ROM) on the product is to be submitted. The information required include, but not	
<ul> <li>(iv) Source &amp; Certificate of Analysis for finished products</li> <li>(iv) Sales record to local and overseas customers presented as the quantities sold to each country per year</li> <li>(v) A copy of the Summary of Product Characteristics/Package Insert</li> <li>(vi) Declaration of source of animal origin and alcohol content (if any).</li> <li>(vii) Good Manufacturing Practice (GMP) certificate</li> <li>(viii) Batch release certificate or certificate of origin (for blood products)</li> <li>(ix) Certificate of suitability, where applicable</li> </ul>	Clinical studies  (ii) Stability studies  (iii) Source for raw material / Active pharmaceutical	
Characteristics/Package Insert  (vi) Declaration of source of animal origin and alcohol content (if any).  (vii) Good Manufacturing Practice (GMP) certificate  (viii) Batch release certificate or certificate of origin (for blood products)  (ix) Certificate of suitability, where applicable	(iv) Source & Certificate of Analysis for finished products (iv) Sales record to local and overseas customers presented as the quantities sold to each country per year	
<ul> <li>(vii) Good Manufacturing Practice (GMP) certificate</li> <li>(viii) Batch release certificate or certificate of origin (for blood products)</li> <li>(ix) Certificate of suitability, where applicable</li> </ul>	Characteristics/Package Insert (vi) Declaration of source of animal origin and alcohol	
	(vii) Good Manufacturing Practice (GMP) certificate     (viii) Batch release certificate or certificate of origin (for blood products)	

Registration with Brunei Darussalam Medicines Control Authority (BDMCA)	
A copy of any of the following:	
<ul> <li>Preference will be given to medicinal products already:</li> <li>Registered with the BDMCA.</li> <li>Submitted for registration with the BDMCA.</li> </ul>	
Product currently / previously supplied to Ministry of Health, Brunei	
Vendor is to submit letter of justification on price increase if the same product has been previous supplied to Ministry of Health from the same supplier / distributor	
Applicable to product manufactured in Australia (NEW)	
Vendor is to provide the following:	
<ol> <li>Manufacturer details</li> <li>Source on the manufacturer details</li> <li>If unable to provide no. 1 and 2, hardcopy of declaration letter stating that the principal is responsible to inform/update any drug-related issues (e.g. drug recalls etc.) for the offered product should any reports/issues arise in Australia</li> <li>A copy of Wholesaler's License Certificate of the principal supplying the product.</li> </ol>	
Local content & Tax Compliance Certificate	
Vendor is to provide a copy of the latest content of the company as well as the updated tax compliance certificate, if applicable	
Çold chain items	
Vendor is to provide records of temperature readings during shipment until point of delivery at State Medical Store	

,	
t .	
Special requirement	
For successful tenderer, vendor is to provide a batch release certificate or certificate of origin (for blood products) for every batch and consignment	
Product Registration No. in any of the *reference countries	
Please state if applicable.	
Product which is registered by at least two drug regulatory agencies in any of the reference countries* will be given preference.	
*The reference countries are Australia, Canada, Malaysia, Singapore, United Kingdom, European Union, and the United States of America	

4 \* ;

A V

٠